Compare HCAT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCAT | ACOG |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 129.4M |
| IPO Year | 2019 | N/A |
| Metric | HCAT | ACOG |
|---|---|---|
| Price | $1.62 | $5.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $4.25 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 924.9K | 74.2K |
| Earning Date | 04-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $306,584,000.00 | N/A |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $1.67 | $3.75 |
| 52 Week High | $5.06 | $10.88 |
| Indicator | HCAT | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 56.02 |
| Support Level | N/A | $4.96 |
| Resistance Level | $2.45 | $6.72 |
| Average True Range (ATR) | 0.14 | 0.63 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 0.97 | 73.10 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.